Clinical Trials Logo
  1. Home
  2. Plaque
  3. NCT02634931

Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex

Plaque Clinical Trial

Official title:
A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex

Clinical Trial Summary

The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients with tuberous sclerosis complex in the open-label trial.

Clinical Trial Description

Tuberous Sclerosis Complex (TSC) is an autosomal dominant hereditary disease that causes benign tumors on the almost whole body (including skin, brain, kidney, lung and heart), behavior disorder as autism, mental retardation and neurologic symptom as epilepsy. Angiofibroma is a TSC-specific facial skin lesion, and hamartoma caused by increase of the component of skin connective tissues and blood vessels. Other skin lesions due to TSC are white macule (hypomelanotic macule), plaque, shagreen patch and ungual fibromas. Current therapeutic methods for angiofibroma are laser and surgical treatments, but there are problems as many relapses, deficiency of evidence, change of pigment, scar and risk of infection.

This is a multicenter and open-label trial. The trial consists of two phase. In the first trial phase for 52 weeks, the efficacy as well as the safety is evaluated. For the second trial phase the trial will be continued until the date of approval of NDA for NPC-12G. The safety is evaluated during the second trial phase, but not the efficacy. Patients who meet all entry criteria for the trial apply 0.2% NPC-12G gel twice a day. Patients will visit at 4 to 5-week intervals for the first 6 months of the first trial phase, and then 3 months intervals thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02634931
Study type Interventional
Source Nobelpharma
Contact
Status Completed
Phase Phase 3
Start date December 2015
Completion date October 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02980497 - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study N/A
Completed NCT02377310 - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography N/A
Not yet recruiting NCT03877705 - Xylitol Chewable Tablets Versus Xylitol Chewing Gum in Geriatric Bedridden Patients Early Phase 1
Completed NCT02666508 - Trial of Toothpaste to Reduce Plaque and Inflammation N/A
Completed NCT04921371 - Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque Phase 1
Completed NCT05138978 - Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples Phase 2
Completed NCT05428189 - Efficacy of the Disclosing Plaque Agent as a Guide to Remove the Oral Biofilm in Orthodontic Patients. N/A
Completed NCT05091216 - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients N/A
Not yet recruiting NCT05031260 - COMORAL® the Oral Irrigation Unit Clinical Trial N/A
Active, not recruiting NCT03022344 - DD2-Coronary Plaque Morphology and Plaque Progression N/A
Completed NCT05121909 - A Study of Experimental Mouthwashes Phase 4
Completed NCT06318819 - Plaque Removal Effectiveness of a Flossing Device Compared to the Conventional Flossing in Adults N/A
Completed NCT03989427 - The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation N/A
Completed NCT04407208 - Convalescent Plasma Therapy in Patients With COVID-19 Phase 1
Completed NCT05821712 - A New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems Phase 3
Completed NCT05239351 - Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects N/A
Active, not recruiting NCT05239117 - Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects N/A
Completed NCT05120141 - A Twelve Week Study of Experimental Mouth Rinses Phase 4
Active, not recruiting NCT05239130 - Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects N/A
Completed NCT05239156 - Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects N/A